American Heart Association

A study in the Journal of the American Heart Association found that people with atrial fibrillation who drank more than five cups of coffee a day performed better on cognitive tests and had brains nearly seven years younger in cognitive age compared to those who drank little to no coffee. Coffee consumption also appeared to lower inflammation in A-Fib patients.

Low-density lipoproteins (LDL) cause atherosclerotic cardiovascular disease, with insights from pathophysiology, genetics, and therapy. Emerging therapies focus on reducing LDL cholesterol and apolipoprotein B. Evaluations of LDL reduction and statin treatment effects are ongoing, with guidelines for acute coronary syndrome and cardiovascular disease prevention emphasizing LDL management. Associations between LDL levels and mortality vary, influenced by inflammation and malnutrition. The lipid paradox, where low LDL is linked to higher mortality in some conditions, is explored. Targeted lipid-lowering therapies and inflammation control are key areas of focus.

The FDA redefines 'healthy' on food labels, including whole fruits, vegetables, whole grains, dairy, eggs, beans, lentils, seafood, lean meat, nuts, and seeds. The new rule aims to simplify nutrition guidance and prevent junk food from being labeled healthy. Companies have until 2028 to comply.

Reprieve Cardiovascular's cardiovascular drainage device showed success in a first-in-human study, facilitating high-volume fluid and sodium removal, with stable kidney function and no acute kidney injury. The company aims to improve patient outcomes and prevent hospital readmissions through precise diuretic administration and real-time physiological monitoring.

Reprieve Cardiovascular announced first-in-human results of the Reprieve System at CSI Focus D-HF, showing safe, rapid fluid and sodium removal, potentially improving ADHF treatment by reducing kidney injury risks and hospital stays.

The cardiac implants market, valued at USD 38.1 billion in 2023, is projected to reach USD 79.2 billion by 2032, growing at a CAGR of 8.5%. Factors driving growth include the rising prevalence of cardiovascular diseases, an aging population, and advancements in medical technology. Governments and regulatory bodies are supporting market growth through investments and stringent regulations, enhancing patient confidence in cardiac implants.

The cardiac implants market was valued at USD 38.1 billion in 2023 and is projected to reach USD 79.2 billion by 2032, growing at a CAGR of 8.5%. Factors driving growth include the rising prevalence of cardiovascular diseases, an aging population, and advancements in medical technology. Key players include Medtronic, Boston Scientific, Abbott Laboratories, and others. North America led the market in 2023, followed by Europe and the Asia-Pacific region.

Arrowhead Pharmaceuticals advances RNAi therapeutics, focusing on TRiM platform and late-stage cardio-metabolic franchise. Key developments include NDA submission for plozasiran to treat FCS and promising Phase 2 data for mixed hyperlipidemia and sHTG. Analysts predict potential approval in 2025, with price targets ranging from $23 to $80 per share.

NYU Langone Health recognized for contributions to patient safety and quality standards, pioneering cancer complication treatment with new microsurgery, and research on BRCA mutation carriers, gut-brain connections, epilepsy treatment, sleep disparities, breast cancer disparities, and humidifier benefits.

References cover biological variation, precision medicine, genetic influences on blood traits, and personalized lab tests, highlighting the importance of understanding individual differences in health and disease.